| Title | PharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025 |
| Category | News Article |
Jin-San Yoo to highlight TIE2-activating antibody’s Phase I progress and broad potential in vascular dysfunction-related diseases
PharmAbcine Inc., a clinical-stage biotech company specializing in next-generation antibody therapeutics, announced on June 9 that it will deliver a corporate presentation at the BIO International Convention 2025(BIO USA), the world’s largest biotechnology partnering event.
Dr. Jin-San Yoo, Founder and President of R&BD at PharmAbcine, is scheduled to speak on Wednesday, June 18, 2025, at 10:15 AM ET in Room 155 at the Boston Convention & Exhibition Center.
In the presentation, Dr. Yoo will provide an overview of PharmAbcine’s proprietary vessel re-normalizer platform and share updates on PMC-403, a novel TIE2-activating human IgG currently in Phase I trials for chronic wet age-related macular degeneration (AMD) patients who are non-responsive to conventional anti-VEGF therapies.
Yoo will emphasize the platform’s potential to restore vascular stability across multiple therapeutic areas, highlighting its compatibility with various treatment modalities and its relevance to difficult-to-treat ophthalmic diseases, including diabetic retinopathy (DR) and diabetic macular edema (DME).
“We look forward to engaging with global partners and investors at BIO USA,” said Dr. Yoo. “PMC-403 has the potential to address a broad spectrum of vascular dysfunction-related diseases—including those associated with aging, cancer, diabetes, infections, genetic disorders, central nervous system (CNS) diseases, and trauma.”
PharmAbcine is actively pursuing global research collaborations to advance the development of its platform and will leverage BIO USA’s one-on-one partnering system to connect with potential partners.
* For more information, please visit the link below
https://www.thebionews.net/news/articleView.html?idxno=15622
* Source : THE BIO (https://www.thebionews.net)
PharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025
Jin-San Yoo to highlight TIE2-activating antibody’s Phase I progress and broad potential in vascular dysfunction-related diseases
PharmAbcine Inc., a clinical-stage biotech company specializing in next-generation antibody therapeutics, announced on June 9 that it will deliver a corporate presentation at the BIO International Convention 2025(BIO USA), the world’s largest biotechnology partnering event.
Dr. Jin-San Yoo, Founder and President of R&BD at PharmAbcine, is scheduled to speak on Wednesday, June 18, 2025, at 10:15 AM ET in Room 155 at the Boston Convention & Exhibition Center.
In the presentation, Dr. Yoo will provide an overview of PharmAbcine’s proprietary vessel re-normalizer platform and share updates on PMC-403, a novel TIE2-activating human IgG currently in Phase I trials for chronic wet age-related macular degeneration (AMD) patients who are non-responsive to conventional anti-VEGF therapies.
Yoo will emphasize the platform’s potential to restore vascular stability across multiple therapeutic areas, highlighting its compatibility with various treatment modalities and its relevance to difficult-to-treat ophthalmic diseases, including diabetic retinopathy (DR) and diabetic macular edema (DME).
“We look forward to engaging with global partners and investors at BIO USA,” said Dr. Yoo. “PMC-403 has the potential to address a broad spectrum of vascular dysfunction-related diseases—including those associated with aging, cancer, diabetes, infections, genetic disorders, central nervous system (CNS) diseases, and trauma.”
PharmAbcine is actively pursuing global research collaborations to advance the development of its platform and will leverage BIO USA’s one-on-one partnering system to connect with potential partners.
* For more information, please visit the link below
https://www.thebionews.net/news/articleView.html?idxno=15622
* Source : THE BIO (https://www.thebionews.net)